International Journal of Endocrinology / 2017 / Article / Tab 4

Research Article

Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors

Table 4

Clinical features of multifocal papillary thyroid cancer in cancer mortality.

Clinical characteristicsAll patientsCancer mortalitySurvival value

Patient number626 (100.0)25 (4.0)601 (96.0)
Gender, female499 (79.7)9 (36.0)490 (81.5)<0.001
Age at diagnosis (year)46.5 ± 13.561.0 ± 13.845.9 ± 13.2<0.001
Mean tumor size (cm)2.1 ± 1.43.2 ± 2.32.0 ± 1.3<0.001
1-month postoperative serum Tg level (ng/mL)184.2 ± 1551.12060.6 ± 6608.4112.8 ± 834.4<0.001
Operative method
 Total thyroidectomy595 (95.0)25 (100.0)570 (94.8)0.244
 Less than total thyroidectomy31 (5.0)31 (5.2)
TNM stage
 Stage I390 (62.3)2 (8.0)388 (64.6)<0.001
 Stages II–IV236 (37.7)23 (92.0)213 (35.4)
Nonremission131 (20.9)24 (96.0)107 (17.8)<0.001
Follow-up period (year)7.1 ± 5.34.9 ± 3.97.2 ± 5.40.032
Postoperative 131I accumulative dose (mCi)153.7 ± 222.2341.1 ± 317.4146.0 ± 213.8<0.001
Radiation therapy28 (4.5)14 (56.0)14 (2.3)<0.001
2nd primary cancer49 (7.8)2 (8.0)47 (7.8)0.974
Diabetes mellitus61 (9.7)61 (10.1)0.094
Lymph node metastasis197 (31.5)14 (56.0)183 (30.4)0.007
Soft tissue invasion153 (24.4)18 (72.0)135 (22.5)<0.001
Distant metastasis39 (6.2)14 (56.0)25 (4.2)<0.001

Number (%); mean ± SD.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.